Hypertension, Metabolic Syndrome X
Conditions
Brief summary
The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome. Moreover, this study will compare serum level of inflammatory markers of the metabolic syndrome after 6 weeks of treatment. An ancillary study performed in one center will assess adipocyte differentiation (PPAR gamma stimulation) in 30 subjects (15 per arm).
Interventions
Sponsors
Boehringer Ingelheim
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patient written informed consent is signed prior to any trial specific procedures participation * male patients \> 18 years * Mean seated SBP \> 130mmHg and/or DBP \> 85mmHg treated with antihypertensive drug(s) * with at least 2 more criteria of metabolic syndrome (NCEPT III). Biological data available within 6 months prior to enrollment visit. * abdominal obesity \> 102 cm at screening * TG \> 1.5 g/l * HDL \< 0.4 g/l * Glycemia \> 6 mmol/l
Exclusion criteria
Patients with any of the following conditions will be excluded from trial: * confirmed type 1 or 2 diabetic patients treated or not * secondary hypertension * Mean seated SBP\>180 mmHg and/or DBP \>110 mmHg at screening * hepatic and/or renal dysfunction as defined by the following laboratory parameters at visit 1: * SGPT (ALT) or SGOT (AST) ¿ twice the upper limit of the normal range * serum creatinine ¿ 2.3 mg/dL (or 203 ¿mol/L) * bilateral renal artery stenosis or renal artery stenosis in a solitary kidney * patients post-renal transplant or with only one functioning kidney * clinically relevant hypokalemia or hyperkalemia at visit 1 * uncorrected volume or sodium depletion at visit 1 * primary aldosteronism * hereditary or known fructose intolerance * biliary obstructive disorders * patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin-II receptor antagonists * history of drug or alcohol dependency within the previous six months * concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form * symptomatic congestive heart failure (New York Heart Academy (NYHA) functional class CHF II-IV) * unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery less than three months prior to informed consent * stroke less than six months prior to informed consent * sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant arrhythmias as determined by the investigator * hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve * known allergic hypersensitivity to any component of the formulations under investigation * concomitant therapy with lithium, cholestyramine or colestipol resins continued after visit 1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the serum adiponectin level at the end of study (6 weeks) between the two groups. | At week 6 |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of serum level of TNF alpha, IL-6, leptine, hsCRP, TG, HDL and blood pressure control between two groups. Adipocyte differentiation in 30 patients (PPAR gamma stimulation) between two groups. | At week 6 |
Countries
France
Outcome results
None listed